从临床试验角度探讨TACE联合索拉非尼在肝癌治疗中的应用价值

doi:10.3877/cma.j.issn.2095-3232.2020.01.015

目的

从临床试验角度探讨TACE联合索拉非尼在肝癌治疗中的应用价值。

方法

选择2010年～2018年全球范围内TACE联合索拉非尼治疗肝癌的4个证据级别最高的随机对照试验（Post-TACE、SPACE、TACE-2、TACTICS研究）。采用对比陈述的方法，分析入组患者人数、肿瘤情况、肝功能、全身状况等一般资料及TACE治疗方式、用药持续时间、主要观察终点、评价方法、中位随访时间等资料，进一步对比不同联合模式下患者的临床获益，找出TACE联合索拉非尼的最佳模式和优选人群。文献综述中采用Kaplan-Meier法绘制生存曲线，采用Cox比例风险回归模型分析比较两组生存状况。

结果

Post-TACE、SPACE、TACE-2研究均以阴性结果告终。TACTICS研究发现，TACE联合索拉非尼组的中位血管侵犯时间、中位肝外转移时间和TACE时间间隔分别为31.3、15.7个月和21.1周，明显长于单纯TACE组的4.0、6.9个月和16.9周（HR=0.26，0.21，0.59；P=0.008，0.006，0.018）。

结论

从临床试验视角来看，TACE联合索拉非尼可能延长不可切除的早中期肝癌患者的无进展生存期，对肿瘤进展起到稳定作用。

关键词: 癌，肝细胞, 经导管肝动脉化疗栓塞, 索拉非尼, 临床试验

Objective

To investigate the application value of TACE combined with sorafenib in the treatment of primary liver cancer (PLC) from the perspective of clinical trials.

Methods

Four randomized controlled trials of TACE combined with sorafenib for PLC with the highest evidence level from 2010 to 2018 were selected globally, named Post-TACE, SPACE, TACE-2, TACTICS study respectively. Using the method of comparative description, the number of patients, tumor condition, liver function, general condition, TACE operation, duration of medication, primary endpoint, evaluation method and median follow-up time were analyzed. The clinical benefits of patients were further compared between different combinations of TACE with sorafenib to explore the optimal one and most eligible patients. In the literature review, the survival curve was delineated by Kaplan-Meier method. The survival status between two groups was analyzed by Cox's proportional hazards regression model.

Results

Negative results were obtained in Post-TACE, SPACE and TACE-2 studies. TACTICS study showed that the median vascular invasion time, median extrahepatic metastasis time and TACE time interval in the TACE combined with sorafenib group were 31.3 months, 15.7 months and 21.1 weeks, respectively, significantly longer than 4.0 months, 6.9 months and 16.9 weeks in the single TACE group (HR=0.26, 0.21, 0.59; P=0.008, 0.006, 0.018).

Conclusions

From the perspective of clinical trials, TACE combined with sorafenib may prolong the progression-free survival of patients with unresectable early and middle stage PLC and play a role in stabilizing the tumor progression.

Key words: Carcinoma, hepatocellular, Transarterial chemoembolisation, Sorafenib, Clinical trial

[1]	杨振宇，杨涛，谭凯，等．肝细胞癌伴门静脉癌栓的治疗进展[J]. 中华肝胆外科杂志，2016, 22(3):206-210.
[2]	文天夫．原发性肝癌诊疗规范（2017年版）解读[J]．中国普外基础与临床杂志，2018, 25(1):32-34.
[3]	杨振宇，杜锡林，杨涛，等．多结节肝细胞癌的基础研究及治疗策略[J]．临床肝胆病杂志，2016, 32(6):1212-1215.
[4]	杨振宇，杜锡林，雷世雄，等．肝切除联合微波固化治疗BCLC-B期肝细胞癌的生存预后分析[J]．中华普通外科杂志，2017, 32(5): 381-385.
[5]	Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J]. Eur J Cancer, 2011, 47(14):2117-2127.
[6]	Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial[J]. J Hepatol, 2016, 64(5):1090-1098.
[7]	Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2017, 2(8):565-575.
[8]	Kudo M. Proposal of primary endpoints for TACE combination trials with systemic therapy: lessons learned from 5 negative trials and the positive TACTICS trial[J]. Liver Cancer, 2018, 7(3):225-234.
[9]	Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4):378-390.
[10]	Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34.
[11]	杨振宇，杨涛，袁利娟，等．肝细胞癌根治术后辅助疗法在预防复发转移中的应用[J]．现代肿瘤医学，2015(19):2862-2864.
[12]	Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J]. Hepatology, 2002, 35(5):1164-1171.
[13]	Wang B, Xu H, Gao ZQ, et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. Acta Radiol, 2008, 49(5):523-529.
[14]	Xiao EH, Guo D, Bian DJ. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells[J]. World J Gastroenterol, 2009, 15(36):4582-4586.
[15]	Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53(3):1020-1022.
[16]	Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival[J]. Hepatology, 2003, 37(2):429-442.
[17]	Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial[J]. J Clin Oncol, 2013, 31(32):4067-4075.
[18]	Pawlik TM, Reyes DK, Cosgrove D, et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29(30):3960-3967.
[19]	Cabrera R, Pannu DS, Caridi J, et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2011, 34(2):205-213.
[20]	Park JW, Koh YH, Kim HB, et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma[J]. J Hepatol, 2012, 56(6):1336-1342.
[21]	Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial[J]. J Hepatol, 2016, 64(5):1090-1098.
[22]	Chao Y, Chung YH, Han G, et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial[J]. Int J Cancer, 2015, 136(6):1458-1467.
[23]	Huang Y, Chen B, Liu N, et al. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis[J]. Int J Clin Pharmacol Ther, 2017, 55(6):498-508.
[24]	Zhang L, Hu P, Chen X, et al. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis[J]. PLoS One, 2014, 9(6):e100305.
[25]	Kudo M, Arizumi T. Transarterial chemoembolization in combination with a molecular targeted agent: lessons learned from negative trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2)[J]. Oncology, 2017, 93 Suppl 1:127-134.

[1]	王兴, 张峰伟. 腹腔镜肝切除联合断面射频消融治疗伴微血管侵犯肝细胞癌的临床研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 580-583.
[2]	杜锡林, 谭凯, 贺小军, 白亮亮, 赵瑶瑶. 肝细胞癌转化治疗方式[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 597-601.
[3]	魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[4]	张其坤, 商福超, 李琪, 栗光明, 王孟龙. 联合脾切除对肝癌合并门静脉高压症患者根治性切除术后的生存获益分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 613-618.
[5]	严庆, 刘颖, 邓斐文, 陈焕伟. 微血管侵犯对肝癌肝移植患者生存预后的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 624-629.
[6]	张文华, 陶焠, 胡添松. 不同部位外生型肝癌临床病理特点及其对术后肝内复发和预后影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 651-655.
[7]	韩宇, 张武, 李安琪, 陈文颖, 谢斯栋. MRI肝脏影像报告和数据系统对非肝硬化乙肝患者肝细胞癌的诊断价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 669-673.
[8]	张维志, 刘连新. 基于生物信息学分析IPO7在肝癌中的表达及意义[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 694-701.
[9]	陈安, 冯娟, 杨振宇, 杜锡林, 柏强善, 阴继凯, 臧莉, 鲁建国. 基于生物信息学分析CCN4在肝细胞癌中表达及其临床意义[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 702-707.
[10]	叶文涛, 吴忠均, 廖锐. 癌旁组织ALOX15表达与肝癌根治性切除术后预后的关系[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 708-712.
[11]	吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
[12]	王峰杰, 王礼光, 廖珊, 刘颖, 符荣党, 陈焕伟. 腹腔镜右半肝切除术治疗肝癌的安全性与疗效[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 517-522.
[13]	张海涛, 贾哲, 马超, 张其坤, 武聚山, 郭庆良, 曾道炳, 栗光明, 王孟龙. 手术切除与射频消融治疗血管周围型单发小肝癌临床疗效分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 523-527.
[14]	吕瑶, 张婵, 陈建华, 张鸣青. 压力控制容量保证通气模式在腹腔镜肝细胞癌切除术中的应用[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 528-533.
[15]	杨秀君, 崔梦莹, 张丹, 曲仙智, 苗云皓, 盛基尧, 郑戈, 刘水, 张学文. 信迪利单抗联合仑伐替尼成功转化治疗不可切除肝癌一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 581-584.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Application value of TACE combined with sorafenib for primary liver cancer from the perspective of clinical trials

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Application value of TACE combined with sorafenib for primary liver cancer from the perspective of clinical trials